REZOLUTE, INC. Adjustments to Additional Paid in Capital, Other
REZOLUTE, INC. (RZLT) reported Adjustments to Additional Paid in Capital, Other of $2.93 million for the 12-month period ending 2016-06-30, per its 10-K filed 2017-09-22.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalOther · last filed 2017-09-22
- REZOLUTE, INC. adjustments to additional paid in capital, other for fiscal 2016 was $2.93M.
| Period end | Adjustments to Additional Paid in Capital, Other 12 month |
|---|---|
| 2016-06-30 | $2.93M 10-K · filed 2017-09-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |